Tickernomics

10y

Historical Returns*:

SPY

27.80%

-58.30%

AIM

SPY

32.66%

-78.62%

AIM

SPY

108.59%

-62.65%

AIM

SPY

302.52%

-99.83%

AIM

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

10.96

4.13

0.27

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-0.46

57.68

3.76

-129.73

0.00

-0.23

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-12825.71

100.00

-11353.12

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

1.5232

-59.65

-73.78

-0.76

Other Earnings and Cash Flow Stats:

AIM ImmunoTech Inc. ( AIM ) Net Income TTM ($MM) is -23.93

AIM ImmunoTech Inc. ( AIM ) Operating Income TTM ($MM) is -27.91

AIM ImmunoTech Inc. ( AIM ) Owners' Earnings Annual ($MM) is 0.00

AIM ImmunoTech Inc. ( AIM ) Current Price to Owners' Earnings ratio is 0.00

AIM ImmunoTech Inc. ( AIM ) EBITDA TTM ($MM) is -27.67

AIM ImmunoTech Inc. ( AIM ) EBITDA Margin is -11353.12%

Capital Allocation:

AIM ImmunoTech Inc. ( AIM ) has paid 0.00 dividends per share and bought back -9.041851 million shares in the past 12 months

AIM ImmunoTech Inc. ( AIM ) has reduced its debt by 0.379 million USD in the last 12 months

Capital Structure:

AIM ImmunoTech Inc. ( AIM ) Interest-bearing Debt ($MM) as of last quarter is 0

AIM ImmunoTech Inc. ( AIM ) Annual Working Capital Investments ($MM) are -4

AIM ImmunoTech Inc. ( AIM ) Book Value ($MM) as of last quarter is 2

AIM ImmunoTech Inc. ( AIM ) Debt/Capital as of last quarter is 12%

Other Balance Sheet Stats:

AIM ImmunoTech Inc. ( AIM ) has 0 million in cash on hand as of last quarter

AIM ImmunoTech Inc. ( AIM ) has 10 million of liabilities due within 12 months, and long term debt 2 as of last quarter

AIM ImmunoTech Inc. ( AIM ) has 57 common shares outstanding as of last quarter

AIM ImmunoTech Inc. ( AIM ) has 0 million USD of preferred stock value

Academic Scores:

AIM ImmunoTech Inc. ( AIM ) Altman Z-Score is -47.43 as of last quarter

AIM ImmunoTech Inc. ( AIM ) Piotroski Score is 4.00 as of last quarter

Corporate Governance:

AIM ImmunoTech Inc. ( AIM ) largest shareholder is ARMISTICE CAPITAL, LLC owning 4330000 shares at 0.87 ($MM) value

MITCHELL WILLIAM M(an insider) Sold 4580 shares of AIM ImmunoTech Inc. ( AIM ) for the amount of $883.94 on 2024-12-19

8.57% of AIM ImmunoTech Inc. ( AIM ) is held by insiders, and 14.07% is held by institutions

AIM ImmunoTech Inc. ( AIM ) went public on 1996-07-12

About AIM ImmunoTech Inc. ( AIM ) :

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.